文献类型：期刊文献

中文题名：dnPD-1(MUC-1+CD 19)CAR-T细胞治疗复发或转移性乳腺癌的临床研究

英文题名：Clinical study of dnPD-1(MUC-1+CD 19)CAR T cells in treatment of recurrent or metastatic breast cancer

作者：宋海侠[1];岳晓华[2];张小平[2];祁海燕[1];孙少伯[2];王碧莹[2];耿广琴[2]

第一作者：宋海侠

机构：[1]甘肃省肿瘤医院,甘肃兰州730050;[2]甘肃中医药大学,甘肃兰州730000

第一机构：甘肃省肿瘤医院,甘肃兰州730050

年份：2021

卷号：29

期号：10

起止页码：1

中文期刊名：中国医学工程

外文期刊名：China Medical Engineering

基金：国家自然科学基金资助课题(81360345);甘肃省卫生行业科研计划项目(GSWSKY-2019-86);甘肃省中医药管理局科研课题(GZK-2018-40);甘肃省卫生行业科研计划项目(GSWSKY-2018-75)。

语种：中文

中文关键词：乳腺癌;CAR-T细胞治疗;粘蛋白1基因;研究

外文关键词：breast cancer;CAR T cell therapy;MUC 1 gene;research

摘要：目的评价dnPD-1[粘蛋白1(MUC-1)+CD19]CAR-T细胞临床治疗复发或转移性乳腺癌的安全性和有效性。方法取患者外周血进行T细胞分离、纯化、激活后,使用病毒载体导入MUC-1的嵌合抗原受体(CAR)基因,获得生产靶向MUC-1 CAR-T的T细胞并扩增,静脉回输注患者体内进行治疗。期间检测患者细胞因子、PET-CT检查变化等并进行疗效评估。结果dnPD-1(MUC-1+CD19)CAR-T细胞治疗使患者的疾病缓解持续时间和无进展生存期可达6个月,整体安全性较好。结论dnPD-1(MUC-1+CD19)CAR-T细胞治疗对复发或转移性乳腺癌有较好的控制,安全性和稳定性良好。
【Objective】To evaluate the safety and efficacy of dnPD-1(MUC-1+CD 19)CAR T cells in the treatment of recurrent or metastatic breast cancer.【Methods】After the peripheral blood T cells were isolated,purified and activated,the MUC-1 CAR gene was introduced by virus vector to obtain and amplify the CAR-T cells targeting MUC-1.The T cells were reinjected into the patients for treatment.The changes of cytokines and PET-CT were detected and the curative effect was evaluated.【Results】The duration of remission and progression free survival of patients with(MUC-1+CD 19)CAR T cell therapy can reach 6 months,and the overall safety is desirable.【Conclusion】dnPD-1(MUC-1+CD 19)CAR T cell therapy is safe and stable in the treatment of recurrent or metastatic breast cancer.